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Abstract
Buruli Ulcer is a neglected tropical disease leading to extensive disabilities and morbidity in
West Africa. In this paper we sought to characterize various strains of Mycobacterium ulcer-
ans (M.ulcerans) with different origins and laboratory passage records while refining a
mouse model for Buruli ulcer. We described, compared and followed the kinetics of the
histo-pathological outcome of infection of a collection of strains at various anatomical sites
of infection in order to find a suitable model for further immunization studies. Moreover we
compared the outcome of infection in C57Bl/6 and Balbc/J mice. Specifically we described
thoroughly one M. ulcerans strain characterized by slow growth rate and limited tissue
necrosis, which presents close ressemblance with the infection kinetics in humans. This
strain caused macrophages as well as T and B cells infiltration, correlating with mycobacte-
rial proliferation at the site of infection as well as in the draining lymph nodes, making it a
suitable strain to screen vaccine candidates efficacy.
Introduction
Buruli ulcer (BU) represents the third most common mycobacterial disease after tuberculosis
and leprosy. The disease has been reported in more than thirty tropical and subtropical coun-
tries, yet children in West-Africa carry the highest burden [1]. The disease often starts as a
painless nodule, oedema or plaque, frequently located on the limbs of patients; it can neverthe-
less affect other body parts [1]. The non-ulcerative form of BU often progresses toward chronic
ulcerative lesions showing characteristic undermined edges with destruction of the subcutane-
ous fat and skin tissue. Although some ulcers can resolve spontaneously, they often result in
severe sequalae such as extensive scars, mobility limitations and in worst cases, amputations.
Mycobacterium ulcerans (M. ulcerans) is the causative agent for BU. It is closely related to
Mycobacterium marinum known to infect fish and other aquatic animals [2]. Extensive analysis
of the genome of M. ulcerans provided evidence for the existence of local clonal complexes in
the BU endemic regions of Africa [3]. Genomic studies indicated that M. ulcerans emerged
from a common ancestor with M. marinum, underwent extensive genome reduction and
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acquired a plasmid encoding a series of polyketide synthases involved in the synthesis of a
macrolide toxin called mycolactone [4]. This toxin possesses immunosuppressive and cytotoxic
properties and is a key virulence factor responsible for most of the pathogenesis of BU [5].
The transmission mode of M. ulcerans has not yet been clearly established [6] [1]. Human
to human transmission does not seem to play a major role, but the occurrence of the disease is
strongly associated with stagnant or slow flowing water bodies. Recent data also suggest the
existence of genetic predisposition which could explain the observation that only a small pro-
portion of exposed individuals seems to develop the disease [7]. M. ulcerans has been detected
in aquatic biting insects and mosquitos. In a Southern Australian endemic area, two mamma-
lian species, the common ringtail (Pseudocheirus peregrinus) and common brushtail (Tricho-
surus vulpecula) possums, have been identified as potential animal reservoirs for M. ulcerans
and are thought to be the origin of transmission through mosquitos [8].
BU is a chronic necrotizing disease with delayed onset; a study in Southern Australia esti-
mated a mean incubation period of 4.5 months (34–264 days). Until recently, wide surgical exci-
sion of lesions was the only treatment option for BU. Since 2004, WHO recommends a
combination drug treatment with rifampicin and streptomycin for eight weeks requiring long
hospital stays (Buruli ulcer, Mycobacterium ulcerans infection, WHO Fact sheet N˚199 August
2012). The morbidity associated with BU in endemic area could be prevented by a vaccine
against M. ulcerans infections. However, it is not clear whether cellular or humoral immune
responses are primarily required to contain the infection. Mycolactone has been shown to
induce necrosis and apoptosis in the tissue surrounding the established infection foci. As a result
infiltrating cells of the innate and adaptive immune system usually do not reach the clusters of
extracellular mycobacteria found in advanced lesions. However, memory cells elicited by a vac-
cine may enable the immune system to eliminate the infection in an early stage when mycolac-
tone levels are still low. In order to profile candidate vaccines, we sought to develop a mouse
model that allows us to follow the course of an experimental M. ulcerans infection. Several stud-
ies have been performed using M. ulcerans infection in mice [9–11]. These studies differ in sev-
eral parameters, including M. ulcerans strains, inoculation dose, site of inoculation and mouse
strains. Here we have systematically compared these parameters with the aim of establishing a
reliable and reproducible mouse model that could be exploited for future immunization studies.
There is evidence that M. ulcerans behaves as an intracellular pathogen within the first
phases of infection before lysing the host macrophage and becoming extracellular within the
surrounding necrotic fibrotic area [12]. We therefore sought to investigate the influence of the
genetic background of infected mice on the development of M. ulcerans infection. In the major-
ity of studies of M. ulcerans infection, BALB/cJ mice, which display a Th2 polarized immune
response, were the model of choice [10][11][9]. Only a few studies describe M. ulcerans infec-
tion in C57Bl/6 mice, whose immune response is characterized by a Th1 polarization [13][14];
moreover these mice are commonly used in M. tuberculosis infection models [15]. Our results
indicate that this difference has only minor impact on the outcome of an M. ulcerans infection.
Materials and Methods
M. ulcerans culture
The M. ulcerans strains NM20/02, NM05/02, NM13/02, NM15/02, NM18/02 were originally
isolated from Ghanaian BU patients as described in Yeboah-Manu et al and were kindly pro-
vided by the Institute for Infectious Diseases in Bern [16,17]. The strains M. ulcerans S1012 and
S1013 were isolated from the ulcerative lesion of a Cameroonian BU patients in 2010[1]. Stocks
were stored at -80˚C. BacTAlert bottles (Biomerieux diagnostic—France) were inoculated and
cultures were grown at 30˚C for 3 weeks and passaged once before preparing the inoculum.
Buruli Ulcer Vaccine Profiling
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For animal inoculation the bacterial suspensions were centrifuged at room temperature for
20 minutes at 1800g. The supernatant was discarded and the pellet was weighed and resus-
pended in sterile phosphate buffered saline (PBS), pH 7.4. Ten-fold dilution series of this sus-
pension were prepared and selected doses were used as inoculum. Serially diluted suspensions
were plated on Middlebrook selective 7H11 plates (Becton-Dickinson, Sparks, MD). Plates
were incubated at 32˚C and colonies were counted after 8 weeks with a final determination at
10 weeks of incubation. While strain NM20/02 has been extensively sub-cultured, all other
strains had only been subcultured a few times (two to five) before use.
Ethical statement
All the mouse experiments were approved by the Ethics and Veterinary office regulations of
the state of Vaud (SAV), Switzerland and documented in the protocol of administrative autho-
rization number 2261. Infection experiments with M. ulcerans were conducted under Bio-
safety-level-3 conditions at the E´cole Polytechnique fe´de´rale de Lausanne (EPFL). Ethical
clearance for the isolation of the M. ulcerans strains NM20/02, NM05/02, NM13/02, NM15/02,
NM18/02 was obtained from the institutional review board of the Noguchi Memorial Institute
for Medical Research, NMIMR, with the federal wide assurance number FWA00001824. Ethi-
cal clearance and aproval of the study including the isolation of S1013 and S1012 were
obtained from the Cameroon National Ethics Committee (N˚041/CNE/DNM/09 and N˚172/
CNE/SE/2011) and the Ethics Committee of Basel (EKBB, reference no. 53/11).
Mice
Groups of 5 mice either C57/Bl6 (Charles River) or BALB/cJ (Janvier), were inoculated subcu-
taneously with 30microliters of bacterial suspension in the left footpad, in the left hock or in
the left ear. We evaluated the hock as a new site of infection specifically to minimize the suffer-
ing of the animal compared to footpad injection as described in Kamala [18]. Mice were moni-
tored and documented every two weeks for development of lesion. At 5, 10 and 15 weeks after
inoculation, mice were sacrificed using CO2 inhalation and the injected tissue harvested asepti-
cally in 10% neutral-buffered formalin solution (approx. 4% formaldehyde, Sigma). After 24
hours, tissue samples were washed with ethanol and stored at 4˚C until further processing.
Footpads, ear and hocks were then incubated in decalcification solution, consisting of 0.6M
EDTA (Ethylenediaminetetraacetic acid) and 0.25M citric acid, for 10 days at 37˚C under
shaking conditions. After decalcification of bones, tissues were embedded in paraffin, cut into
5μm sections using a microtome, and retrieved on glass slides.
Histology and immunohistochemistry
For histopathology, foot pad, hock and ear 5-μm thin sections were deparaffinised, rehydrated,
and stained with Haematoxylin/Eosin (HE, Sigma, J.T. Baker) or Ziehl-Neelsen/Methylene
blue (ZN, Sigma) according to WHO standard protocols. Stained sections were mounted with
Eukitt mounting medium (Fluka). Pictures were taken with a Leica DM2500B microscope or
with an Aperio scanner.
For immunohistochemistry, sections were deparaffinized and rehydrated. Endogenous per-
oxidase was blocked with 3% H2O2 for 10 min and unspecific binding was prevented by incu-
bation with blocking serum matching the secondary antibody host. Subsequently, slides were
pretreated by the hot-borate antigen retrieval method (0.02 M, pH 7) [19] and incubated at
room temperature with monoclonal antibodies against CD45R (B cells; clone RA3-6B2) (Sero-
tec), monocytes/macrophages (Mo-Ma; clone MOMA-2) (Serotec), CD3 cells (T cells; clone
CD3-12) (Serotec), neutrophils (clone NIMP-R14) (Abcam). Afterwards, sections were
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incubated for 30 min with a corresponding biotinylated secondary antibody (Vector Laborato-
ries) and for an additional 30 min with streptavidin-horseradish peroxidase conjugate (Vectas-
tain ABC kit; Vector Laboratories). Staining was performed using Vector NovaRed (Vector
Laboratories) and Meyer’s hematoxylin as a counterstain (Sigma). Sections were mounted
with Eukitt mounting medium (Fluka). Pictures were taken with a Leica DM5000B micro-
scope. Histo-pathological photographic pictures displayed are representative of results
obtained for each experiments.
Results
Various degrees of virulence of M. ulcerans strains
In order to establish an experimental M. ulcerans mouse infection model for the evaluation of
the protective efficacy of candidate vaccine formulations, we compared the virulence of seven
different clinical M. ulcerans isolates from Ghana and Cameroon. While one strain (NM20/02)
had been recurrently sub-cultured in vitro, others had either been passaged only a few times
(NM05/02, NM13/02, NM15/02, NM18/02), namely less than five times, or cryopresevered
after only one or two subculturing steps following isolation from the lesions of BU patients
(S1012, S1013) (Table 1).
We hypothesized that the amount of extra-cellular matrix injected alongside the bacteria
could influence the outcome of infection and the degree of inflammation. Hence we chose to
standardize our inoculum according to wet mass while determining a posteriori the amount of
CFU contained within the innocula. Strains grown in BacT Alert bottles were centrifuged,
resuspended in PBS and between 2.4x104 and 8x105 colony forming unit (CFU) were injected
in a volume of 0.03ml subcutaneously in the left footpad of C57/Bl6 mice (S1 Fig). Footpads of
mice were monitored every two weeks for the development of swelling, redness and ulceration.
The first signs of footpad swelling appeared between two and five weeks after inoculation in all
mice. Ulceration never occurred in NM20/02 infected mice while perfusion and ultimately
open lesions arose between two to four weeks after the first signs of swelling in 5 out of 5 mice
of each group inoculated with the low-passaged strains, namely NM05/02, NM13/02, NM15/
02, NM18/02. As shown in Fig 1, noticeable differences were seen in the ability of each strain
Table 1. Origin and subculture history of M.ulcerans strains.
Strain Country of origin Extent of subculture
NM20/02 Ghana extensive
NM13/02 Ghana moderate
NM05/02 Ghana moderate
NM15/02 Ghana moderate
NM18/02 Ghana moderate
S1013 Cameroon low
S1012 Cameroon low
doi:10.1371/journal.pone.0167059.t001
Fig 1. Comparison of macroscopic signs of infection in mice inoculated by various M. ulcerans strains. Suspensions of M. ulcerans from seven
strains from Ghana and Cameroon were injected subcutaneous (s.c.) in the footpad of C57Bl/6 mice. Footpad swelling at week 4 after infection is shown.
doi:10.1371/journal.pone.0167059.g001
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to induce inflammation. In contrast to all other isolates, the extensively cultivated strain
NM20/02 persisted for prolonged periods of time in the footpads without causing massive
pathology. This strain showed the highest growth rate of all isolates in vitro and had retained
the capacity to produce mycolactone (S1 Fig and data not shown). While a mild swelling of the
footpad became apparent four to five weeks after injection of 8x105 CFU of NM20/02, none of
the inoculated mice injected with this strain developed an ulcerative lesion. This attenuated
phenotype did not lead to massive tissue destruction but evolved slowly and mirrored in this
respect more closely the progressive evolution of human BU lesions, NM20/02 may represent
a particularly suitable indicator strain for vaccine efficacy testing. Hence we characterized the
progression of the infection provoked by NM20/02 in further detail.
ZN staining of thin sections of the footpads five weeks after inoculation revealed solid-
stained acid-fast bacilli (AFB) located in the subcutis of the skin tissue close to the site of injec-
tion (Fig 2). AFB were surrounded by infiltrates composed of numerous polymorphonuclear
Fig 2. Macroscopic and microscopic signs of infection and inflammation in mice infected with M.
ulcerans. The upper panel shows photograph of a C57Bl/6 mouse footpad 5 weeks after injection with M.
ulcerans (NM20/02) (A) and the non-injected control footpad (B). Middle panel shows the corresponding
5micrometer thick paraffin embedded footpad slices stained with Ziehl-Neelsen (ZN) staining. Finally, the
lower panel shows the same footpad slices stained with Hematoxylin Eosin (H&E). Arrows show the bacterial
foci (ZN) and the inflamed tissue (H&E) of the lesion.
doi:10.1371/journal.pone.0167059.g002
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(PMN) leukocytes and located in close association with irregularly shaped blue stained nuclei.
Compared to the control footpad, hematoxylin-eosin (H&E) staining of the infected footpads
revealed signs of extensive dermal edema as well as coagulative necrosis around the bacterial
foci. The infiltrated area was loosely organized in a central necrotic core mainly composed of
neutrophilic debris with granular cells characterized by vacuolar degeneration and seen in
close proximity to the bacterial foci (Fig 3C and 3D). Macrophages formed a loose and irregu-
lar network around this neutrophilic necrotic core, while T and B cells more distantly located
from the bacteria looked intact with a well-defined cytoplasm and a round shaped nucleus (Fig
3A and 3B). B cells were often seen in clusters but typical organized granuloma structure was
not observed [20].
Kinetics of M. ulcerans infection in mice
To assess whether strain NM20/02 can multiply and persist for an extended period of time
within the host, we followed the fate of inocula injected into the footpad in C57/Bl6 mice over
time. In order to monitor the development of the infection after M. ulcerans NM20/02 inocula-
tion, we designed a time course experiment in which we assessed bacterial growth by histologi-
cal staining at various time points of the experiment. After injection, Ziehl-Neelsen (ZN)
staining of sections from the site of injection, i.e. footpad, demonstrated clear multiplication of
the bacteria, increasing from week 4 to week 10 and assembling progressively into bacterial
foci (Fig 4A and 4B). However beaded bacteria were observed 15 weeks after inoculation show-
ing heterochromatic nuclei of PMN leukocytes surrounding dying bacteria (Fig 4C). These
observations may suggest a halt in bacterial burden and a decrease in bacterial viability. While
leukocytic infiltration was extremely abundant at week 5, it seemed to decrease by week 10 but
Fig 3. Infiltration of leukocytes within the footpad infected with M. ulcerans. Immunohistochemistry was
performed on 5 micrometer paraffin embedded sections of footpad of mice infected with a suspension of M.
ulcerans (NM20/02) in order to identify the nature of the leukocytic infiltrate present within and around the
bacterial foci. B cells were stained with anti-CD45R antibody (A), T cells with anti-CD3 antibody (B),
Macrophages with MOMA (C) and neutrophils with anti-Ly6G/Ly6C (D).
doi:10.1371/journal.pone.0167059.g003
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Fig 4. Evolution of bacterial load over time after infection by M.ulcerans. ZN stainings of 5 micrometer
thick slices of paraffin embedded footpad of a mouse infected s.c. with M. ulcerans NM20/02 4 weeks (upper),
10 weeks (middle) and 15 weeks (lower) after infection.
doi:10.1371/journal.pone.0167059.g004
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persisted until week 15, the last time point evaluated. On the other hand, a follow-up experi-
ment where 2.8x105 CFU/mL of M. ulcerans NM20/02 was innoculated in the ear of BALB/cJ
mice showed that solid stained AFB and sustained infiltration could still be found 7.5 months
after injection (Fig 5). While some areas clearly showed beaded bacteria indicative of poor via-
bility, it revealed that mycobacterial antigens are able to persist and to maintain sustained
inflammation for several months after inoculation.
In order to assess the optimal site of injection for M. ulcerans in the mouse, we compared
the outcome after injection of strain NM20/02 in the hock, footpad and ear of C57/Bl6 mice.
Development of lesions at the hock are thought to obstruct movement of animals less than
lesions at the footpad [18]. As shown in Fig 6, injection in the footpad and in the ear readily
induced a macroscopically detectable inflammation that was not seen in the hock. Further-
more injection in the hock proved unpractical, since the bacterial foci were difficult to localize
during histo-pathological analyses (Fig 6 middle panel). Injection of the ear is technically
Fig 5. Long-term persistence of M.ulcerans bacteria after infection. ZN staining of 5 micrometer thick paraffin embedded sections of mice injected
subcutaneously in the ear with M. ulcerans NM20/02. Tissue samples were harvested 7.5 months after infection.
doi:10.1371/journal.pone.0167059.g005
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demanding and resulted in rapid loss of tissue (Fig 6 lower panel). For routine use, the footpad
met all the criteria for a safe and reproducible method of injection, inducing a macroscopically
observable and microscopically measurable infection.
To assess the effect of infection dose, mice were injected with a serial 10-fold dilution of an
NM20/02 suspension at the three different sites of injection. We have chosen to display here
the most representative histopathology analysis pictures, namely the ear of BALB/cJ mice,
as this site provided the most visually assessable macroscopic changes following the infection,
illustrating best the dose effect. A similar dose response experiment was performed in the foot-
pad and hock of both strains of mice and provided similar findings (S2 Fig). While the
highest dose resulted in rapid and fulminating swelling with loss of ear tissue and ultimately
development of a scar (data not shown), a 10x diluted inoculum resulted in a severe wound
but no loss of tissue (Fig 7 left panel). Finally a 100x dilution dose only induced limited
swelling of the ear and signs of redness (Fig 7 middle panel) compared to the negative
control showing no sign of inflammation (Fig 7 right panel). At the microscopic level,
marked differences in leukocytic infiltration, edema formation and necrotic area reflected
the macroscopic outcome and the number of ZN positive bacilli as well as their dissemination
within the tissue. It is noticeable that the highest dose injected resulted in tissue discharge and
subsequent wound closure leaving healthy and less affected tissue with scarce bacilli. It is
not clear whether the rare bacilli detected within the healthy tissue were viable and could
potentially reactivate the infection. Similar findings were observed at the other injection sites
(cf. S2 Fig).
In the tissue of BALB/cJ mice inoculated with lower doses of NM20/02 (D1/10 –right),
numerous AFB were found loosely associated with necrotic nuclei. On the other hand, in mice
receiving the D1/100 dilution dose, AFB were primarily located nearby polymorphonuclear leu-
kocytes. Immunohistochemistry analysis revealed a large necrotic area composed of neutro-
philic debris in close proximity with the bacilli (Fig 8D). T cells and macrophages on the other
hand were located in the periphery of the bacterial foci (Fig 8B and 8C).
Outcome of M. ulcerans infection in different mouse strains
In an attempt to examine the influence of a primarily Th2 versus Th1 oriented immune
responses, we compared the development of the infection in BALB/cJ and C57Bl/6 mice after
inoculation of footpads with 6.6x104 CFU of strain NM20/02. BALB/cJ mice showed less
Fig 6. Evaluation of various sites of infection for M.ulcerans infection. A solution of M. ulcerans NM20/
02 was injected s.c. in three different sites of C57Bl/6 mice, namely footpad (upper panel), hock (middle
panel) and ear (lower panel). The following time points after infection are displayed: week 2 (A), week 4 (lower
panel—B) or 5 (upper and middle panel—B) and week 10 (C). The corresponding ZN staining of 5 micrometer
thick slices of paraffin embedded footpad, hock and ear at week 4 (B) and week 10 (C) after infection are
shown.
doi:10.1371/journal.pone.0167059.g006
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swelling and less infiltration than C57Bl/6 mice at early time points (Fig 9). Moreover bacterial
multiplication in BALB/cJ mice was slightly lower than in C57Bl/6 mice (Fig 9). Furthermore
the proportion of solid stained AFB was higher in C57Bl/6 mice than in BALB/cJ mice (Fig 9).
Finally a clear difference in lymph node cellularity was observed between BALB/cJ and
C57Bl/6 mice as illustrated in Fig 10 where draining lymph nodes from infected C57/Bl6 mice
were markedly more enlarged than draining lymph nodes from infected BALB/cJ mice. Fur-
thermore an increased number and size of germinal centers in the draining lymph nodes of
C57Bl/6 mice compared to the draining lymph nodes of BALB/cJ mice suggested a more vigor-
ous immune response in the C57Bl/6 mice (Fig 10 and data not shown). Western blotting anal-
yses and ELISAs with bacterial lysates as well as recombinant M. ulcerans proteins revealed in
none of the two mouse strains the development of a significant M. ulcerans specific antibody
titer even after 15 weeks of infection (data not shown).
Fig 7. Dose effect of M.ulcerans inoculum on the outcome of infection. Photographs of ear (upper panel)
and the corresponding ZN staining of 5μm thick slices of paraffin embedded ear (lower panel) of mice infected
with various dilutions (D = 1/10 and D = 1/100) of M. ulcerans NM20/02 suspension 9 weeks after infection.
doi:10.1371/journal.pone.0167059.g007
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Conclusion and Discussion
The overall goal of this study was to describe features of a chronic M. ulcerans mouse infection
model suitable for the profiling of vaccine candidates.
In our study it is noteworthy that the quantification of bacteria injected was based on wet
biomass weight evaluation and subsequent CFUs determination, which does not always allow
precise quantification of live single M. ulcerans bacteria in the inoculum. The structure of the
mycobacterial cell wall in addition to the presence of extracellular matrix and the resulting ten-
dency to aggregate in clumps complicates the accurate measurement by classical methods
commonly used in microbiology such as optical density measurements. We sought to mini-
mize this factor by using the exact same conditions of culture and preparation of the bacteria
inoculated in each experiment and to normalize inoculates by the weight of their wet mass
prior to injection. While automated image analysis for quantification of bacterial cells from
digital microscope images, RNA isolation of the tissue at the site of infection followed by
reverse transcription qPCR and eventually CFU determination from tissue harvested at the
site of infection and at various time points would help determining the viability and quantifica-
tion of the bacteria at the endpoint of infection, they were beyond the capacity and scope of
this study.
Based on a thorough histological analysis of several parameters at different time points in
the time course of the infection for each of the strains available in this study, we were able to
identify the most suitable strain for further immunization studies. Infection with strain NM20/
Fig 8. Infiltration of leukocytes within the ear infected with M. ulcerans. ZN staining (A) and
Immunohistochemistry (B-D) were performed on 5 micrometer paraffin embedded ear sections of Balb/c mice
sacrificed at week 9 after infection with a suspension of bacteria diluted at D1/10 in order to identify the nature
of the leukocytic infiltrate present within and around the bacterial foci. T cells were stained with anti-CD3
antibody (B), macrophages with MOMA (C) and neutrophils with anti-Ly6G/Ly6C (D).
doi:10.1371/journal.pone.0167059.g008
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02 resulted in the development of edematous lesions with widespread lymphocytic infiltration,
multiplication and persistence of the bacteria for several weeks without leading to open ulcera-
tion and tissue loss. Hence strain NM20/02 caused mild infection and massive local inflamma-
tion shown by immune cells infiltration, which should make it possible to characterize
mechanisms of immune protection elicited by vaccination. On the other hand, strains charac-
terized by low passage numbers in vitro display a higher virulence inducing greater inflamma-
tion and rapid necrosis in the host tissue precluding analysis of immunological process at the
histological level. These differences could not be attributed to mycolactone production since
all strains produced similar amounts of mycolactone (data not shown).
Our results confirmed that the footpad is the site of choice in the mouse for a well-defined,
consistent and reproducible infection since it is most suitable to monitor both infiltration and
multiplication of the bacteria by histo-pathological analysis.
By comparing the infection outcomes in two different mouse genetic backgrounds, we
showed that C57Bl/6 mice display more extensive leukocytic infiltration and bacterial growth
than BALB/cJ mice. The size and cellularity of the draining lymph nodes in C57Bl/6 mice were
markedly higher, indicative of a predominant cellular immune response. While polarization
Fig 9. Influence of mouse strain on the outcome of M.ulcerans infection. A solution of 6.6x104 CFU of M.
ulcerans was injected in the footpad of C57Bl/6 (A) and Balb/cJ mice (B). Footpad pictures are shown at week
8 after infection (upper panel). ZN staining of 5μm thick histology slices of paraffin embedded footpads show
infiltration area (blue nuclei—middle panel) and bacterial load (pink rod-shape bacilli—lower panel) 12 week
after infection in C57Bl/6 (A) and Balb/c (B) mice.
doi:10.1371/journal.pone.0167059.g009
Buruli Ulcer Vaccine Profiling
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towards a Th1 response is thought to play a preponderant role in fighting against mycobacte-
rial infections, its role may be more complex in M. ulcerans infection and requires further elu-
cidations. Eventually passive immunization with various antibodies directed against the 18kDa
heat shock protein (MUL2232) and the 27kD laminar binding protein (MUL3720) either in
BALB/cJ or in C57Bl/6 mice failed to protect mice against M. ulcerans infection (data not
shown).
Supporting Information
S1 Fig. CFUs from innoculum of M.ulcerans strains. A solution of M.ulcerans from 6 differ-
ent strains of various geographical origins was injected in the footpad of C57Bl/6 mice. CFUs
are represented as CFU/ml of innocula for each strain at the time of injection.
(TIF)
Fig 10. Lymph node cellularity of Balb/Jc vs C57Bl/6 mice. H&E staining was performed on 5 micrometer paraffin embedded sections of
draining (right) and non-draining lymph nodes.
doi:10.1371/journal.pone.0167059.g010
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S2 Fig. Dose response of NM20/02 in the footpad. C57Bl/6 mice were injected with various
dilutions (D = 1/10 and D = 1/100) of M. ulcerans NM20/02 suspension. Photographs of the
footpad at week 2 after infection (left panel) and ZN staining of 5μm thick slices of paraffin
embedded tissue 5 weeks after infection (right panel, magnification x100 and x400).
(TIF)
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